CLLS
Closed
Cellectis Sa
1.55
+0.03 (+1.97%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 1.525
Day's Range: 1.51 - 1.62
Send
sign up or login to leave a comment!
When Written:
1.93
Cellectis SA is a French biotechnology company founded in 1999 that specializes in developing immunotherapies based on gene editing technology. The company is focused on developing CAR-T cell therapies for the treatment of cancer and other diseases. Cellectis uses its proprietary gene editing technology, TALEN, to modify immune cells and create CAR-T cells that can recognize and attack cancer cells. The company has partnerships with pharmaceutical companies, including Pfizer and Servier, to develop and commercialize its CAR-T therapies. Cellectis is also developing gene-edited allogeneic CAR-T cells, which are derived from healthy donors and can be used to treat multiple patients. The company is headquartered in Paris, France, and has operations in the United States.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








